key: cord-0335329-umyfv9yj
authors: Abdelnabi, Rana; Foo, Caroline S.; Jochmans, Dirk; Vangeel, Laura; De Jonghe, Steven; Augustijns, Patrick; Mols, Raf; Weynand, Birgit; Wattanakul, Thanaporn; Hoglund, Richard M.; Tarning, Joel; Mowbray, Charles E.; Sjö, Peter; Escudié, Fanny; Scandale, Ivan; Chatelain, Eric; Neyts, Johan
title: The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
date: 2021-11-05
journal: bioRxiv
DOI: 10.1101/2021.11.04.467077
sha: dc9218e256cdc2fbc57c4fb6f9403ed6f842a3be
doc_id: 335329
cord_uid: umyfv9yj

There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels.

There is an urgent need for potent and safe antiviral drugs for the treatment and prophylaxis of SARS-35

CoV-2 infections. Highly efficacious and safe viral proteases inhibitors have largely contributed to the 36 effective treatment of infections with HIV and HCV. Coronaviruses have two proteases, the main 37 protease Mpro (or 3CL protease) and the papain-like protease 1 . Mpro is a cysteine protease which 38 cleaves the two polyproteins (pp1a and pp1ab) of SARS-CoV-2 at eleven different sites, resulting in the 39 the various non-structural proteins, which are key for viral replication 2, 3 . The substrate of Mpro is a 40 distinct glutamine at the P1 site (Leu-Gln/Ser, Ala, Gly), no known human proteases recognize this 41 cleavage site 4,5 . Mpro can thus be considered as a highly attractive drug target for the development of 42 SARS-CoV-2 antivirals. 43

Pfizer reported recently that a SARS-CoV Mpro inhibitor which they developed in 2002 during the SARS-44

CoV-1 outbreak, is also effective against SARS-CoV-2 6 . Since the oral bioavailability of this compound 45 is insufficient, an oral version, PF-07321332 (PF-332), was developed 7 . PF-332 potently inhibits the in 46 vitro SARS-CoV-2 (USA_WA1/2020) replication as well as the replication of coronaviruses. The 47 compound was also shown to exert antiviral activity in BALB/c mice infected with a mouse adapted 48 SARS-CoV-2 variant (MA10) 7 . 49 We here report on the in vitro activity of PF-332 against different SARS-CoV-2 variants of concern (VoC) 50 (including in human airway epithelial cultures) and on the efficacy of the drug in Syrian Golden 51 hamsters (including in a transmission model) that had been infected with either the beta or the delta 52 variant of SARS-CoV-2. 53

In vitro antiviral activity of PF-332 against SARS-CoV-2 VoCs including in human airway epithelial 55

The in vitro antiviral activity of PF-332 against the four main SARS-CoV-2 VoC was first assessed in Vero 57

We here report that PF-332 (Pfizer) an oral SARS-CoV-2 Mpro inhibitor, protects Syrian Golden 119 hamsters against challenge with both the beta and the delta VoC of SARS-CoV-2. To guide the hamster 120 studies, we first assessed the in vitro antiviral activity of PF-332 against the four different VoCs. Nearly 121 equipotent activity against the different variants was observed and this independent of the cell line 122 used. PF-332 (at 1 µM) resulted also in full inhibition of the replication of the alpha VoC replication in 123 primary human airways epithelial cells grown at the air-liquid interface which is a physiologically 124 relevant model. 125

In hamsters infected with either the beta or the delta variant, a dose of 250 mg/kg BID of PF-332 126 reduced infectious virus titres in the lungs to undetectable levels. Half the dose (125 mg/kg BID) was 127 highly effective in some but not all animals. Pharmacokinetic analysis corroborated these observations; 128 indeed trough plasma PF-332 concentrations are maintained above the in vitro EC50 for the 250mg/kg 129 BID dose but not consistently in animals that received the lower dose. Interestingly treatment of SARS-130

CoV-2 (delta) infected index hamsters completely prevented transmission to untreated co-housed 131 sentinels. If such findings could be translated to the human situation, it may be assumed that 132 treatment of infected patients will largely reduce a possible transmission to their contacts. Such 133 strategy may have important consequences, for example in the context of a household when one or 134 more members are infected and others not. 135

The antiviral effect of PF-332 in mice infected with a mouse-adapted SARS-CoV-2 strain was recently 136 reported 7 . Oral BID dosing of PF-332 (at 300 and 1000 mg/kg) reduced titres of infectious virus in the 137 lungs by respectively 1.4 and 1.9 log10 TCID50/ml as compared to the vehicle-treated group 7 . A marked 138 reduction in lung histopathology was also observed in the lungs of PF-332-treated mice 7 . Obviously, 139 even very high doses of PF-332 in mice do by far not achieve the pronounced antiviral potency as 140 achieved in the hamster model (maximally 1.9 log10 reduction in infectious virus titres in the lungs of 141 mice treated with 1000 mg/kg BID versus 4.2-4.8 log10 reduction in the lungs of hamsters treated with 142 250 mg/kg BID). This emphasizes the importance to assess the potential of drug candidates in various 143 preclinical models. It should be noted that clinical isolates of the beta and the delta variant were used 144 in the hamster study versus a mouse-adapted strain in the mouse studies. 145

Pharmacokinetic analysis revealed a relatively fast terminal elimination half-life of PF-332 of 4-5 hours. 146

Co-administration with ritonavir, a potent CYP 3A4 inhibitor, might reduce the metabolism of PF-332 147 and increase the overall exposure, and/or reduce the dose needed. PF-332 is currently in clinical trials 148 in combination with ritonavir (for example NCT05047601). Clearly, in the experiments presented here 149 the exposures following administration of the highest dose were sufficient to achieve a pronounced 150 antiviral effect. We will further explore whether the combined effect of PF-332 with ritonavir may 151 result in a dose reduction of PF-332 in the hamster SARS-CoV-2 infection model. 152

Other direct antiviral drugs are in development for the treatment of COVID-19. As of today, only one 153 antiviral drug has approved for the treatment of COVID-19, Veklury® (remdesivir). This injectable 154 (intravenous dosing) treatment is exclusively indicated for hospitalized patients 9 . In a recent press 155 release it was announced that early administration of Veklury® to high risk patients with mild to 156 moderate symptoms reduces the likelihood of hospitalization with 87%. The active form remdesivir, 157 which is the 5'-triphosphate of the parent nucleoside, is incorporated by the viral RNA dependent RNA 158 polymerase (RdRp) into the growing RNA chain leading to chain termination 10 Lifesciences) that was formulated as 40 mg/ml in a vehicle containing 40% PEG400 (Sigma) in sterile 202 distilled water. PF-07321332 (from Wuxi) was used only in the delta variant hamster study and it was 203 formulated as 40 mg/ml in a vehicle containing 60% PEG400 (Sigma) in sterile distilled water. In these 204 studies, the crystalline form of the active product ingredient (API) was characterized by differential 205 scanning calorimetry (DSC) (data not shown). X-ray powder diffraction (XRPD) would be however 206 required to fully characterize the crystalline form of each API used in in vivo studies. 207

The assay using Vero E6 cells was derived from a previously established SARS-CoV assay 17 

Viral RNA in the apical wash was isolated using the Cells-to-cDNA II cell lysis buffer kit (Thermo Fisher 249 Scientific, catalogue no. AM8723). Briefly, 5 µL wash fluid was added in 50 µL lysis buffer, incubated at 250 room temperature (RT) for 10 min and then at 75•C for 15 min. 150 µL nuclease-free water was 251 additionally added to the mixture prior to RT-qPCR. Together with the samples, a ten-fold serial 252 dilution of the corresponding virus stock was extracted to later generate a standard curve for the qPCR. Based on this standard curve the amount of viral RNA can be expressed as median Tissue Culture 254 infective dose (TCID50 ) equivalents per insert (TCID50eq/insert), and the lowest point of the linear part 255 of the standard curve (highest Ct value) determines the lower limit of quantification (LLOQ). The RT-256 qPCR was performed using iTaq universal probes one-step kit (Bio-Rad, catalogue no. 1725141), and a 257 commercial mix of primers for N gene, manufactured at IDT Technologies (catalogue no. 10006606). 258

The reaction (final volume: 20 µL) consisted of 10 µL one-step reaction mix 2x, 0.5 µL reverse 259 transcriptase, 1.5 µL of primers and probes mix, 4 µL nuclease-free water, and 4 µL viral RNA. The RT-260 qPCR was executed on a Lightcycler 96 thermocycler (Roche), starting at 50°C for 15 min and 95°C for 261 2 min, followed by 45 cycles of 3 sec at 95°C and 30 sec at 55°C. 262

The hamster infection model of SARS-CoV-2 has been described before 15, 19 . by RT-qPCR and end-point virus titration, respectively as described before 16 . 280

Two groups of index hamsters were infected with Delta variant and treated with either vehicle or PF-282 332 at 250 mg/kg/dose twice daily starting from D0. On day1 pi (just after the morning dose), each 283 index hamster was co-housed with a contact hamster (non-infected, non-treated hamsters) in one 284 cage and the co-housing continued until day 3 pi The treatment of index hamsters was continued until 285 day2 pi. At day 3 pi, all the index hamsters were euthanized whereas all the contact hamsters were 286 euthanized the day after (i.e. day 4 pi of index) as mentioned before and lungs were collected to assess 287 viral loads. 288

Histology 289

For histological examination, the lungs were fixed overnight in 4% formaldehyde and embedded in 290 paraffin. Tissue sections (5 μm) were analyzed after staining with hematoxylin and eosin and scored 291 blindly for lung damage by an expert pathologist. The scored parameters, to which a cumulative score 292 of 1 to 10 was attributed, were the following: congestion, intra-alveolar hemorrhagic, intra-alveolar 293 edema, apoptotic bodies in bronchus wall, necrotizing bronchiolitis, perivascular edema, 294 bronchopneumonia, perivascular inflammation, peribronchial inflammation and vasculitis. 295

For in vivo antiviral efficacy, we want to detect at least 1 log10 reduction in viral RNA levels in treated 297 subjects compared to the untreated, infected control group. Group size was calculated on the 298 independent t-test with an effect size of 2.0 and a power of 80% (effect size = deltamean/SD = 1 log10 299 decrease in viral RNA/0.5 log10), resulting in 5-6 animals/group. Sample sizes maximized considering 300 limits in BSL3 housing capacity, numbers of animals that can be handled under BSL3 conditions, and 301 availability of compounds. 302

The number of animals and independent experiments that were performed is indicated in the legends 304 to figures. The analysis of histopathology was done blindly. All statistical analyses were performed 305 using GraphPad Prism 9 software (GraphPad, San Diego, CA, USA). Statistical significance was 306 determined using the non-parametric Mann Whitney U-test or student T-test. P-values of <0.05 were 307 considered significant. 308 The percentages of the free concentration were respectively calculated using following formulas: 320

Where 'd' represents the dilution factor and 'AREA' the chromatographic peak area of the analyte. As 322 the percentage of the coefficient of variation (CV) of the Internal standard is below 10%, the analyte 323 area is considered for calculation instead of internal standard-normalised peak area. The apparent in vitro intrinsic clearance is then calculated using the following formulas 343

Where T1/2 is the half-life and CLint, app the apparent in vitro intrinsic clearance. 346

The pharmacokinetic samples used for population pharmacokinetic analysis were collected in female 348 Syrian hamsters from two satellite studies (study 1 and study 2) with uninfected hamsters sourced 349 from Hylasco Biotechnology -a Charles River licensee) and LIVEON BIOLABS (Bangalore). In both 350 studies, the pharmacokinetic samples were collected at 0, 0.5, 1, 3, 6, 12, 24h after the dose was given 351 orally. In study 1, the samples were collected from 8 animals that received a single oral dose of 50 352 mg/kg (n=4) and 125 mg/kg (n=4) formulated as a homogenous suspension in 0.5% methylcellulose 353 (w/v) in water. In study 2, samples were collected from 6 animals that received a single oral dose of 354 125 mg/kg (n=3) and 250 mg/kg (n=3) formulated as a homogenous suspension of 40% PEG 400, 60% 355

MilliQ water. The animals were fasted 12h before the dose and until 4h after dose. The data from the two studies were modelled simultaneously using nonlinear mixed-effects approach 364 in NONMEM, v7.4 (Icon Development Solution, Ellicott City, MD) 20,21 . One-, two-, and three-365 compartment models were evaluated to describe the structural disposition model of PF-332. First-366 order and zero-order absorption models were evaluated to describe drug absorption. Relative 367 bioavailability was fixed to unity and added into the model by estimating the inter-individual variability. 368

In order to improve the translational aspect of the model, body weight was implemented on all 369 clearance and volume parameters using a fixed allometric function with an exponent of 0.75 and 1 for 370 clearance and volume, respectively. Differences in the pharmacokinetic properties between the two 371 satellite studies were expected due to the manufacturing process of PF-332, essentially resulting in 372 different formulations of PF-332. These differences were evaluated as a categorical covariate on all 373 pharmacokinetic parameters. Additionally, dose was also evaluated as a continuous linear covariate in 374 the model. The covariate investigation was performed using a stepwise forward inclusion (P=0.05, 375 ∆OFV = -3.84), followed by a stepwise backward elimination (P=0.001, ∆OFV= -10.83) procedure. 376

Parameter precision was obtained using a bootstrapping approach with 1,000 re-sampled datasets 377 stratified by study. Predictive performance was evaluated with simulation-based diagnostics 378 (Supplementary Fig. S3) . 379

The pharmacokinetic parameters from the population pharmacokinetic model were used to simulate The open circles represent the observed PF-332 concentrations. Solid black lines represent the 50th 561 percentiles of the observations, and dashed black lines represent the 5th and 95th percentiles of the 562 observations. The shaded areas represent the 95% confidence intervals of each simulated percentile 563 (n =1,000). 564 565 

Emerging coronaviruses: Genome structure, replication, and 439 pathogenesis

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

An overview of severe 443 acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics 444 and small molecule chemotherapy

The substrate specificity of SARS coronavirus 3C-like proteinase

The SARS-CoV-2 main protease as drug target. Bioorganic and 448 Medicinal Chemistry Letters 30

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential 450

An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of 452

A robust SARS-CoV-2 replication model in primary human epithelial cells at 454 the air liquid interface to assess antiviral agents

Use Authorization for Potential COVID-19 Treatment

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-460

CoV-2 pathogenesis in mice. bioRxiv : the preprint server for biology

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

The combined treatment of Molnupiravir and Favipiravir results in a 465 potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of 468

Concern in a Hamster Infection Model

Favipiravir at high doses has potent antiviral activity in SARS-CoV-470

−infected hamsters, whereas hydroxychloroquine lacks activity

Comparing infectivity and virulence of emerging SARS-CoV-2 variants in 473

Development of a homogeneous screening assay for automated detection of 475 antiviral agents active against severe acute respiratory syndrome-associated coronavirus

A novel method for high-throughput screening to 478 quantify antiviral activity against viruses that induce limited CPE

STAT2 signaling restricts viral dissemination but drives severe pneumonia 481 in SARS-CoV-2 infected hamsters

Perl-speaks-NONMEM (PsN) -A Perl module for 483 NONMEM related programming

PCluster: A modeling environment and cluster infrastructure for NONMEM

We thank Carolien De Keyzer, Lindsey Bervoets, Thibault Francken, Birgit Voeten, Dagmar Buyst, Niels 414Cremers for excellent technical assistance. We are grateful to Piet Maes for kindly providing the SARS-415CoV-2 strain used in this study. We thank Jef Arnout and Annelies Sterckx (KU Leuven